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ABSTRACT: 
Recent work has provided evidence for genetic and molecular heterogeneity in colorectal 
cancers (CRCs) arising in patients with Lynch syndrome (LS), dividing these into two groups: 
G1 and G2.  In terms of mutation and gene expression profile, G1 CRCs bear resemblance 
to sporadic CRCs with microsatellite instability (MSI), whereas G2 CRCs are more similar 
to microsatellite stable CRCs.  Here we review the current state of knowledge on pathways 
of precursor progression to CRC in LS and how these might tie in with the new findings.  
Immunotherapy is an active field of research for MSI cancers and their potential use for 
cancer therapy for both sporadic and LS MSI cancers is discussed. 
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ABBREVIATIONS 
APC Adenomatous polyposis coli (protein) 
CAR Chimeric antigen receptor 
CRC Colorectal cancer 
CTL Cytotoxic T-lymphocytes 
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CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
FDA Food and Drug Administration (USA) 
FSP Frame-shift peptide 
LS Lynch syndrome 
LS-CRC Lynch syndrome colorectal cancer 
MMR DNA mismatch repair 
MSI Microsatellite instability 
MSS Microsatellite stability 
MHC Major histocompatibility complex 
PD-1 Programmed cell death protein-1 
PD-L1 Programmed death-ligand 1 
TCR T-cell receptor 
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Lynch syndrome  
Lynch syndrome (LS) is probably the most common hereditary cause of cancer in 
humans: a genetic condition with a prevalence of at least 1 in 200, that predisposes to 
various cancers, most frequently colorectal (CRC) and endometrial adenocarcinoma [1].  It 
is caused by constitutional (“germline”) mutations in one of four DNA mismatch-repair (MMR) 
genes: MLH1, MSH2, MSH6 and PMS2.  Such heritable mutations, when combined with a 
sporadic somatic mutation of the normal allele, lead to a deficiency of DNA mismatch repair 
that results in the accumulation of genetic length-changing mutations at microsatellites – so-
called ‘microsatellite instability’ (MSI).  This is accompanied by an incidental 100 – 1000-fold 
increase in mutation rate, but more importantly a reduced susceptibility to apoptosis induced 
by DNA damage recognised by the MMR pathway, and it is this which confers a strongly 
selectable Darwinian advantage to such cells.  A subset (~14%) of sporadic colon cancers 
which arise from right-sided serrated lesions are also MMR-deficient, and thus have MSI, 
because of hypermethylation of the MLH1 gene’s promoter [2].  In contrast, sporadic rectal 
cancers with MMR-deficiency are rare and most rectal cancers with loss of MMR are due to 
LS [3,4].  LS accounts for 3.3% of bowel cancers in the UK, a similar proportion to Denmark 
(2.8%) and the USA (3.1%) [5–7]. 
The number of mutations reported in MMR genes varies [8].  This is a consequence of 
mutations in MLH1 and MSH2 conferring the highest risks, MSH6 mutations less so, and 
PMS2 mutations least of all, so cases of LS identified on the basis of family history are 
mostly found to have mutations in MSH2 or MLH1.  However, this may change as case 
finding by systematic testing of incident cancers becomes the norm [e.g. 3].  So far, gene, 
gender, age, and previous cancer have all been identified as variables in LS cancer risk [10], 
as well as various environmental and lifestyle factors [1]. 
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Molecular heterogeneity of Lynch syndrome tumours 
Whilst research in sporadic CRC has focussed on delineating molecular heterogeneity, 
little work has been done on such heterogeneity in LS-CRC.  Previously, it was assumed 
that CRCs occurring in LS patients were all part of the same disease process.  However, 
recent studies have identified at least two precursors of LS-CRC.  Firstly, via adenomatous 
polyp formation in which APC mutations (and other genetic or epigenetic changes) which 
occur early, and probably sporadically, and drive conventional polypoid adenoma formation.  
Subsequent loss of MMR in LS patients leads to invasive adenocarcinoma via more genetic 
mutations.  Secondly, a separate pathway in which MMR deficiency occurs within single 
non-dysplastic crypt foci, that subsequently acquire more genetic changes to become flat 
intra-mucosal neoplastic lesions, that are more difficult to diagnose endoscopically [11].  
Intriguingly, evidence is coming forward of a third pathway, related to the first two, 
comprising a subset of lesions that initially proceed along the second pathway, but which on 
acquisition of somatic APC mutations, secondary to the MMR deficiency, become dysplastic 
and polypoid [12].  It is thought that approximately half of the CRCs in LS may evolve from 
these flat, non-polypoid, neoplasms to form sub-mucosal “immediately invasive” cancers.  
These are often associated with CTNNB1 mutational activation, instead of APC inactivation, 
although mutations of ASTE1/HT001, AIM2 and BAX may also contribute to the progression 
of MMR-deficient precursors into MMR-deficient cancers.  Moreover, these must arise at a 
slow rate, given the 10,000 or so MMR-deficient crypts which have an inactivated second 
MMR allele in a LS large bowel, and yet LS patients develop only zero, one or perhaps two 
CRCs in a lifetime [13,14].  This is in contradistinction to the original school of thought that 
LS-CRCs must derive from very rapidly growing adenomas – an understandable logical 
consequence of assuming all CRCs derive from polypoid adenomas. 
In turn, this starts to explain recent findings that surveillance colonoscopy in LS patients 
only reduces CRC-related mortality in LS by half, mostly by downstaging, whilst making no 
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discernible impact on the rate at which LS-CRCs occur – in complete contrast to the situation 
in the general population undergoing screening, where adenoma removal very significantly 
impacts on future CRC incidence [15,16].  Significantly, individuals who have inherited 
mutations in both copies of the DNA repair genes MSH2, MLH1, MSH6, PMS2, MSH3 and 
MUTYH can develop multiple colorectal adenomas, but patients with a mutation in only one 
copy of these genes do not. 
Further new evidence now supports the contention that, in addition to different precursor 
lesions, distinct molecular and cellular subtypes of LS-CRC exist.  Writing in this edition of 
The Journal of Pathology, Binder and colleagues utilise CRC resection specimens from LS 
patients to demonstrate at least two distinct genetic subtypes of LS-CRC, termed G1 and 
G2 [17].  The DNA sequencing data shows that G1 tumours have a different mutation 
spectrum compared to G2 tumours, with higher mutation numbers and greater MSI.  
Interestingly, G1 cancers share these characteristics with sporadic MSI CRC, whereas the 
mutational profile of G2 cancers tends more to resemble that of microsatellite stable (MSS) 
sporadic CRC.  Additionally, a higher proportion of G1 cancers arise on a background of 
germline MLH1 mutation compared with G2 cancers.  These findings suggest that, even 
within LS, varying degrees of mutation frequency and MSI exist, consistent with multiple 
pathways to carcinogenesis in LS. 
The authors also perform gene expression analysis on these two LS tumour groups.  The 
G1 reference mucosa has upregulated transcription of genes associated with inflammatory 
pathways, whereas G1 tumours have strong upregulation of cell cycle and proliferation-
associated genes.  In contrast, G2 reference mucosa and tumours show a more 
heterogeneous expression signature with either a stromal or mucosal transcriptional 
programme.  The inflammatory signature in G1 reference mucosa is characterised by 
overexpression of various T- and B-lymphocyte markers (e.g.  CD3, CD4, CD8 and CD19), 
and this is backed up by strong CD4+ staining demonstrated by immunohistochemistry.  
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Moreover, G1 reference mucosa shows higher expression of genes related to MHC antigen 
presentation and of chemokine receptor-ligand pairs compared with G1 tumours.  These 
data suggest that G1 tumours undergo transcriptional reprogramming to dysregulate the 
immune response and hence evade immune destruction.  The differences between G1 and 
G2 LS-CRCs are summarised and compared to sporadic CRC in Table 1. 
 
Role of the Immune System in Tumour Immunosurveillance and Immune Escape 
The link between the immune system and cancer was probably first recognised in the 
nineteenth century, when Rudolf Virchow noticed an infiltrate of leucocytes within tumours 
[18].  However, the exact role the immune system plays is complex and our understanding 
of this is continually evolving.  Somewhat paradoxically, both ‘avoiding immune destruction’ 
and ‘tumour-promoting inflammation’ are now regarded as hallmarks of cancer [19], 
suggesting that the immune system has dual roles in protecting from and promoting 
carcinogenesis.  The mechanisms by which cancer cells avoid immune destruction can be 
conceptualised as a continual process of ‘immunoediting’ and split into three phases: 
elimination, equilibrium and escape [20]. 
MSI cancers with high mutation rates producing many mutant proteins tend to be 
particularly immunogenic and are typically associated with a strong lymphocytic infiltrate [21].  
Moreover, they tend to show overexpression of immune-checkpoint proteins (e.g. PD-1 and 
CTLA-4) [22], and early-stage clinical trials show promising results for anti-tumour efficacy 
of immune-checkpoint inhibitors in the treatment of advanced MSI CRC [23,24].  It is 
hypothesised that this immunogenicity is due to the generation of a multitude of neo-
antigens that are recognised as ‘foreign’ and trigger a strong immune response [25].  With 
deficiency of MMR, cells develop a characteristic mutator phenotype, and accumulate indel 
mutations within microsatellites and other repetitive sequences.  If this occurs within coding 
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DNA, it can lead to a frameshift within the translational reading frame and hence synthesis 
of novel frameshift peptides (FSP) that can act as tumour-specific antigens.  This hypothesis 
is backed up by previous work that shows tumour-infiltrating T-lymphocytes exhibiting 
reactivity against predicted FSPs are present in sporadic MSI, but not MSS, CRCs [26].  
Interestingly, peripheral FSP-reactive T-cells are also identified in LS patients without CRC, 
but not individuals without LS, or CRC patients with cancers that do not have MMR 
deficiency.  This shows that patients with LS are ‘auto-immunised’ against FSP neo-antigens 
prior to cancer formation, and may explain the better survival [27] and reduced rate of 
metastasis [21] seen in LS-CRCs compared to sporadic CRCs. 
In the work by Binder et al.  [17],  G1 reference mucosa is shown to be more 
immunogenic than that of G2 with a greater CD4+ infiltrate and greater expression of 
immune response-associated genes.  Furthermore, even within the G1 group, expression 
of MHC class II genes and the predicted number of FSP neo-antigens (from sequencing 
data) rises as a function of mutational load.  This supports a conceptual model whereby 
MMR deficiency leads to hypermutation within coding repetitive sequences, which in turn 
leads to generation of FSPs and consequently a strong anti-tumour immune response.  Such 
a strong immune response was not seen in G2 reference mucosa, supporting the contention 
that there is heterogeneity concerning the mutation frequencies and degree of MSI in LS. 
G1 tumours, in contrast with matched reference mucosa, show reduced expression 
of MHC class I and II genes as well as reduced infiltration with CD4+ cells [17], suggesting 
that they have undergone immune escape through reduced presentation of FSP neo-
antigens.  Such immune escape in MSI CRC has previously been linked to mutation in genes 
that regulate MHC class I (e.g. B2M) and class II (e.g. CIITA, RFX5) function [28,29].  
Additionally, in this work, the authors describe recurrent mutations in AIM2 (an upstream 
regulator of MHC class II function [30]) as a mechanism for reduced FSP presentation.  
Interestingly, G1 tumours show reduced expression of the T-cell immune checkpoint 
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proteins, PD-1 and CTLA-4, compared to reference mucosa, consistent with a reduced 
infiltration with lymphocytes.  Conversely, sporadic MSI CRCs tend to have a strong 
lymphocytic infiltrate and show increased expression of immune-checkpoints [21,22].  
Overall, these findings are consistent with marked immunoediting of G1 CRCs that arise in 
LS.  In the early stages of carcinogenesis, the immune system is able to keep small foci of 
neoplastic cells in check (elimination phase).  However, the inevitable accumulation of 
somatic mutations in MMR-deficient cells leads to mechanisms to avoid immune destruction 
and the progression to CRC (equilibrium and escape phases) [see Figure 1]. 
 
Implications for cancer therapy and clinical practice 
Clinically, MMR-deficient cancers tend to be immunogenic and therefore have the 
potential to be targeted with specific immunotherapy.  MSS CRCs, on the other hand, are 
not as immunogenic and would be less likely to respond to immunotherapy.  Although LS-
CRCs have MMR deficiency, their response to immunotherapy may be more difficult to 
predict.  G2 CRCs are less immunogenic, bearing resemblance to sporadic MSS CRCs, and 
therefore might be less likely to respond.  G1 CRCs arise in a highly immunogenic 
environment, suggesting that they would be good candidates for treatment with 
immunotherapy.  However, these tumours have undergone immune escape with reduced 
antigen presentation and reduced lymphocytic infiltrate, meaning that some 
immunotherapies may not be as effective as compared with sporadic MSI CRCs. 
Clinical trials are already underway for the use of immune-checkpoint inhibitors such 
as pembrolizumab and nivolumab for MSI CRC [23,24].  Another approach, based on the 
idea of ‘auto-immunisation’ in patients with LS, is to develop a vaccine against common FSP 
neo-antigens expressed by MSI CRCs.  Such a vaccine has completed phase I/IIa clinical 
trials with long-term results awaited [31].  Different approaches for vaccine delivery have 
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also been tried, including peptide loading of patient’s monocyte-derived dendritic cells ex 
vivo and administration to the patient as a cellular vaccine  [32].  In addition, as adoptive 
transfer of ‘CAR T-cells’ (cytotoxic T-lymphocytes engineered to express a chimeric antigen 
receptor recognising a particular antigen [33]) has recently gained FDA approval for the 
management of various haematological malignancies [34,35], then such an approach has 
the potential to be used in MSI CRC by creating engineered T-cells, either with an 
engineered T-cell receptor (TCR) or CAR, against FSP neo-antigens.  Adoptive transfer of 
cytotoxic T-cells, with an engineered TCR against a common MSI FSP, has demonstrated 
efficacy in a xenograft mouse model [36], but a trial in humans is yet to be conducted.  
Although not yet experimentally tested, CAR T-cells against membrane-associated FSP 
neo-antigens could represent an ideal way to target G1 LS-CRCs and sporadic MSI CRCs 
that have undergone immune escape, as there is no requirement for FSP neo-antigens to 
be presented by MHC class I (since the immunoglobulin domain of a CAR can directly target 
FSPs). 
The implications of these findings of LS tumour heterogeneity include the need for 
greater use of MMR analysis in all LS and sporadic MSI cancers, both biopsies and 
resections, including CRCs, endometrial cancers and other LS-related cancers.  This should 
include combined MMR immunohistochemistry and tumour MSI testing for LS screening, 
prognosis, prediction of treatment responsiveness (both conventional chemotherapy and 
immunotherapies), and pre-operative planning of appropriate surgical operations.  Binder et 
al’s work [17] also argues for further work to establish whether this should also now involve 
further tumour testing for G1 versus G2 MSI subtypes, along with quantitative analysis and 
characterisation of tumour infiltrating lymphocytes for more sophisticated prediction of 
responsiveness to the emerging range of immunotherapies.  Moving forward into the era of 
digital pathology, more advanced image-analysis techniques will facilitate such a 
quantitative description of tumour infiltrating lymphocytes, and prognostic parameters such 
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as the ‘Immunoscore’ [37] are likely to become an integral part of the pathology report in 
CRC. 
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Table 1: Comparison of properties of G1 and G2 LS-CRC (as defined by Binder et al.  [17]) 
with sporadic CRC, both MSI and MSS.  Data all from [17]. 
 
Colorectal cancers 
 
Lynch Syndrome Sporadic 
 
MSI (G1) MSI (G2) MSI MSS 
Relative 
Mutation 
Numbers 
High Low High Low 
Fraction of 
microsatellites 
exhibiting 
deletions 
High Low High Low 
Gene expression 
profile 
DOWN-
regulation of 
immune 
system and 
inflammatory 
genes. 
UP-regulation 
of cell cycle 
and 
proliferation 
genes 
UP-regulation 
of mucosal 
and stromal 
genes 
UP-regulation 
of cell cycle and 
proliferation 
genes 
UP-regulation 
of cell cycle and 
proliferation 
genes 
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Figure 1: Mechanisms of Immunoediting in MMR-deficient CRC.  Both G1 CRCs in LS 
and sporadic MSI CRCs elicit a strong immune response and undergo significant 
immunoediting.  Cytotoxic T-lymphocytes (CTL) are able to recognise immunogenic 
frameshift peptides (FSPs) that are synthesised in MMR-deficient cells as a result of MSI.  
However, tumour cells may evolve mechanisms to prevent immune destruction including 
inhibition of CTLs by upregulating expression of immune-checkpoints (e.g.  PD-L1) or 
through various genetic mutations leading to loss FSP antigen presentation.    
 
 
